Literature DB >> 8906366

Prognostic relevance of localization and grading in intracranial ependymomas of childhood.

R I Ernestus1, R Schröder, H Stützer, N Klug.   

Abstract

Intracranial ependymomas represent one of the most frequent brain tumors in childhood. Their preferred midline localization and their often controversially discussed classification prompted the present study of 67 intracranial ependymomas in children less than 15 years of age who were operated on from 1951 to 1990. Clinical data and follow-up of all children were retrospectively analyzed by calculation and statistical comparison of progression-free survival (PFS). According to the WHO classification as revised in 1993, 1 grade I subependymoma, 38 grade II ependymomas, and 28 grade III anaplastic (malignant) ependymomas were differentiated. Grade II ependymomas were predominantly located in the IV ventricle and in the supratentorial midline, which often made complete tumor resection impossible. In contrast, the majority of grade III tumors, most often situated in the cerebral hemispheres, could be totally removed. Operative mortality was higher in grade II than in grade III tumors. After recovery from operation, PFS was mainly determined by the histological grading. Median postoperative PFS was 120 months in grade II, but only 18 months in grade III ependymomas (P = 0.1417). Thus, despite varying therapeutic concepts, analysis of this 40-year collective study confirms the prognostic relevance of localization and WHO grading in the case of intracranial ependymoma in children.

Entities:  

Mesh:

Year:  1996        PMID: 8906366     DOI: 10.1007/bf00261604

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  34 in total

1.  Ependymoma: a follow-up study of 101 cases.

Authors:  S J Mork; A C Loken
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

2.  Ependymomas and choroid plexus papillomas.

Authors:  N RINGERTZ; A REYMOND
Journal:  J Neuropathol Exp Neurol       Date:  1949-10       Impact factor: 3.685

3.  Ependymomas and ependymoblastomas in children.

Authors:  G J Dohrmann; J R Farwell; J T Flannery
Journal:  J Neurosurg       Date:  1976-09       Impact factor: 5.115

4.  Historical development of the classification of brain tumours and the new proposal of the World Health Organization (WHO).

Authors:  K J Zülch
Journal:  Neurosurg Rev       Date:  1981       Impact factor: 3.042

5.  Ependymomas of childhood. I. Histological survey and clinicopathological correlation.

Authors:  H M Liu; J Boogs; J Kidd
Journal:  Childs Brain       Date:  1976

6.  Intracranial ependymomas in childhood. Survival and functional results of 47 cases.

Authors:  A Pierre-Kahn; J F Hirsch; F X Roux; D Renier; C Sainte-Rose
Journal:  Childs Brain       Date:  1983

7.  Supratentorial ependymomas in childhood: clinicopathological findings and prognosis.

Authors:  R I Ernestus; O Wilcke; R Schröder
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

8.  Supratentorial lobar ependymomas: reports on the grading and survival periods in 80 cases, including 46 recurrences.

Authors:  D Afra; W Müller; F Slowik; O Wilcke; H Budka; L Turoczy
Journal:  Acta Neurochir (Wien)       Date:  1983       Impact factor: 2.216

9.  Intracranial ependymoma in children: analysis of prognostic factors.

Authors:  J K Chiu; S Y Woo; J Ater; J Connelly; J M Bruner; M H Maor; J van Eys; M J Oswald; R Shallenberger
Journal:  J Neurooncol       Date:  1992-07       Impact factor: 4.130

View more
  17 in total

1.  Large supratentorial cortical ependymoma in a child.

Authors:  Alaattin Yurt; Mehmet Selçuki; Ali Riza Ertürk; Ali Küpelioglu
Journal:  Clin Med Res       Date:  2010-03

2.  Intracranial ependymomas in childhood: recurrence, reoperation, and outcome.

Authors:  Matthieu Vinchon; Pierre Leblond; Rémy Noudel; Patrick Dhellemmes
Journal:  Childs Nerv Syst       Date:  2004-12-14       Impact factor: 1.475

3.  Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups.

Authors:  Y Hirose; K Aldape; A Bollen; C D James; D Brat; K Lamborn; M Berger; B G Feuerstein
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

4.  Predicting which children are at risk for ependymoma relapse.

Authors:  Kristina Sowar; Jennifer Straessle; Andrew M Donson; Michael Handler; Nicholas K Foreman
Journal:  J Neurooncol       Date:  2006-03-31       Impact factor: 4.130

5.  Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure.

Authors:  Natsuo Oya; Yuta Shibamoto; Yasushi Nagata; Yoshiharu Negoro; Masahiro Hiraoka
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

6.  The use of neoadjuvant chemotherapy to achieve complete surgical resection in recurring supratentorial anaplastic ependymoma.

Authors:  Elvis Terci Valera; Helio Rubens Machado; Antonio Carlos Santos; Ricardo Santos de Oliveira; David Araújo; Luciano Neder; Luiz Gonzaga Tone
Journal:  Childs Nerv Syst       Date:  2004-08-27       Impact factor: 1.475

7.  Supratentorial ependymoma: disease control, complications, and functional outcomes after irradiation.

Authors:  Efrat Landau; Frederick A Boop; Heather M Conklin; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-11       Impact factor: 7.038

Review 8.  Classification and controversies in pathology of ependymomas.

Authors:  Catherine Godfraind
Journal:  Childs Nerv Syst       Date:  2009-02-11       Impact factor: 1.475

Review 9.  Ependymoma.

Authors:  Charles Teo; Peter Nakaji; Patricia Symons; Vivienne Tobias; Richard Cohn; Robert Smee
Journal:  Childs Nerv Syst       Date:  2003-05-22       Impact factor: 1.475

Review 10.  WHO Grade II and III supratentorial hemispheric ependymomas in adults: case series and review of treatment options.

Authors:  Toba N Niazi; Elizabeth M Jensen; Randy L Jensen
Journal:  J Neurooncol       Date:  2008-11-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.